Current Report Filing (8-k)
June 21 2022 - 10:31AM
Edgar (US Regulatory)
0001601280
false
0001601280
2022-06-21
2022-06-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
———————
FORM 8-K
———————
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 21, 2022
———————
MediXall Group, Inc.
(Exact name of registrant as specified in
its charter)
———————
Nevada |
333-186282 |
33-0864127 |
(State or Other Jurisdiction |
(Commission |
(I.R.S. Employer |
of Incorporation) |
File Number) |
Identification No.) |
2929
East Commercial Blvd., PH-D, Fort Lauderdale, Florida 33308
(Address of Principal Executive Office) (Zip Code)
(954) 440-4678
(Registrant’s telephone number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
N/A |
N/A |
N/A |
Indicate by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth company ☐ |
|
If an emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On June 21, 2022, MediXall Group, Inc. issued a letter to its shareholders
written by Noel J. Guillama-Alvarez, as the new Chairman of the Board of Directors and Interim CEO of MediXall Group, Inc. A copy of the
letter is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MediXall Group Inc. |
|
|
|
|
|
|
Dated: June 21, 2022 |
By: |
/s/ Timothy Hart |
|
Name: |
Timothy Hart |
|
Title: |
Chief Financial Officer |
MediXall (CE) (USOTC:MDXL)
Historical Stock Chart
From Jun 2024 to Jul 2024
MediXall (CE) (USOTC:MDXL)
Historical Stock Chart
From Jul 2023 to Jul 2024